ArticleGlobal cardiology science & practice2025
BRASH syndrome in a patient with coexisting anxiety disorder and long-term benzodiazepine use: A case report.
Article in Global cardiology science & practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBRASH syndrome represents a constellation of symptoms characterized by bradycardia, renal impairment, AV block, shock, and hyperkalemia. This vicious cycle leads to rapid clinical worsening and requires optimal management. This case illustrates the importance of rapid decision-making and management to navigate the critical phase of BRASH syndrome. CASE SUMMARY: A 73-year-old woman with a pre-existing anxiety disorder presented with sudden generalized fatigue and several episodes of dyspnea. The initial electrocardiogram (ECG) revealed bradycardia (30 beats/min) with episodes of sinus arrest, RBBB, and PVC bigeminy. Laboratory tests indicated hyperkalemia, hyponatremia, elevated blood urea nitrogen, and elevated creatinine levels. Long-term alprazolam and recent bisoprolol use were documented in this patient. Dopamine was administered for inotropic and vasopressor support. Calcium gluconate was given, and a temporary pacemaker was considered. After three days of hospitalization, the patient's condition improved, with an ECG showing a heart rate of 66 beats per minute and improved renal function following the correction of hyperkalemia. DISCUSSION: We recommend considering BRASH syndrome in patients presenting with bradycardia and hyperkalemia with recent AV nodal blocking agent use. In our case, bisoprolol was the most likely precipitating factor. The patient's long-term alprazolam use was also noted; while any potential modulatory role remains speculative, it may warrant further investigation. It is important to recognize this so that appropriate synergistic treatment for all contributing factors can be implemented, rather than focusing on a single component.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.